AI Article Synopsis
Article Abstract
Itraconazole, the first orally active triazole antifungal agent, was tested in 185 cases of acute or chronic (recurrent) dermatophytosis. The skin infections were divided into two major diagnostic groups: tinea corporis/tinea cruris (91 cases) and tinea pedis/tinea manuum (94 cases). Each patient was randomly assigned to a regimen of 50 or 100 mg of itraconazole daily. Of the cases of tinea corporis and/or tinea cruris, 94% responded to 50 mg of itraconazole daily and 96% to 100 mg daily. The effects of therapy were evident earlier when 100 mg daily was given. Of the cases of tinea pedis and/or tinea manuum, 80% responded to 50 mg of itraconazole daily and 94% to 100 mg. Again, improvement was seen sooner with the 100-mg regimen. Only five patients (2.9%) reported minor adverse reactions. Hematologic and blood-biochemical parameters were monitored before treatment and at biweekly intervals thereafter in 37 patients; no significant abnormalities were observed. Thus, either 50 or 100 mg of itraconazole daily constitutes effective treatment for dermatophytoses. Since the larger dosage induces a faster response, it should be evaluated further.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/clinids/9.supplement_1.s104 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Invasive aspergillosis in an immunocompetent patient: A retrospective case report and review of the literature.
J Infect Dev Ctries
November 2024
Department of Neurosurgery, Shaoxing People's Hospital, Zhejiang, 312000, China.
Introduction: Invasive aspergillosis (IA) is rare in immunocompetent patients. We present the case of a 44-year-old female with IA invading the lungs, mediastinum, heart, and brain, with a disease duration of 11 years.
Case Presentation: The patient was initially diagnosed with lung aspergillosis that had invaded the mediastinum on October 8, 2008.
Secondary Myiasis in an Immunocompetent Patient With Severe Chromoblastomycosis.
Cureus
October 2024
Family Medicine, St. Joseph's Regional Medical Center, Paterson, USA.
This is the case of chronic chromoblastomycosis (CBM) in a 61-year-old male from the Dominican Republic (DR) with extensive cutaneous eruptions over multiple areas of the body including bilateral lower extremities and the flank extending to the back. A 61-year-old male with a history of morbid obesity, chronic kidney disease stage III, and well-controlled hypertension presented to the family medicine clinic for the evaluation of chronic painful skin lesions on his legs and torso. The lesions began 19 years prior, following a flood in the Dominican Republic (DR) where he was living at the time.
View Article and Find Full Text PDFDeconvoluting zavegepant drug-drug interactions: A phase I study to evaluate the effects of rifampin and itraconazole on zavegepant pharmacokinetics.
Clin Transl Sci
December 2024
Pfizer Inc., Groton, Connecticut, USA.
Zavegepant is a calcitonin gene-related peptide receptor antagonist for acute migraine treatment. This Phase I, open-label, fixed-sequence study evaluated the effects of itraconazole (a strong cytochrome P450 3A4 [CYP3A4] and P-glycoprotein [P-gp] inhibitor) on the pharmacokinetics of intranasal/oral zavegepant and the effects of rifampin (a strong inducer of CYP3A4 and P-gp; and an inhibitor of organic anion transporting polypeptide 1B3 [OATP1B3]) on oral zavegepant in healthy participants. In the intranasal/oral zavegepant-itraconazole cohort, participants received a single 10-mg dose of zavegepant nasal spray on Day 1, followed by oral zavegepant (50 mg) on Day 3.
View Article and Find Full Text PDFClinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug-Drug Interactions.
Clin Pharmacol Ther
November 2024
Clinical Pharmacology and Nonclinical Development, Mirati Therapeutics Inc. (A Bristol Myers Squib Company), San Diego, California, USA.
Adagrasib is a potent, highly selective, orally available, small molecule, covalent inhibitor of G12C mutated KRAS. As both a substrate and strong inhibitor of cytochrome P450 (CYP) 3A4, adagrasib inhibits its own CYP3A4-mediated metabolism following multiple dosing, resulting in time-dependent drug-drug interaction (DDI) liabilities. A physiologically-based pharmacokinetic (PBPK) model was developed and verified using a combination of physicochemical, in vitro and clinical pharmacokinetic (PK) data from healthy volunteers and cancer patients.
View Article and Find Full Text PDFInhalation of itraconazole mitigates bleomycin-induced lung fibrosis via regulating SPP1 and C3 signaling pathway pivotal in the interaction between phagocytic macrophages and diseased fibroblasts.
J Transl Med
November 2024
Department of Pulmonology and Orthopedic Surgery, Children's Hospital, School of Medicine, Zhejiang University, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
Background: Idiopathic pulmonary fibrosis (IPF) stands as a significant contributor to global mortality rates. Presently, there exists a dearth of effective anti-fibrotic treatments for this condition. While itraconazole (ITR) has exhibited potential in mitigating pulmonary fibrosis, its oral administration is hampered by unfavorable pharmacokinetics, which elevate the risk of adverse reactions, thus limiting its clinical utility.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!